Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study
IntroductionAlthough pegylated interferon (PEG-IFN) has been widely used in the treatment of polycythemia vera (PV), there is still a significant variability in its specific dosage and administration.MethodsThis single-center retrospective study assessed the efficacy and safety of PEG-IFN in JAK2V61...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1586839/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | IntroductionAlthough pegylated interferon (PEG-IFN) has been widely used in the treatment of polycythemia vera (PV), there is still a significant variability in its specific dosage and administration.MethodsThis single-center retrospective study assessed the efficacy and safety of PEG-IFN in JAK2V617F-positive PV patients using a dose de-escalation strategy.ResultsFrom 2018 to 2022, 110 PV patients received PEG-IFN treatment and monitored for JAK2V617F variant allele frequency (VAF) over 12 months, with 95.4% achieving complete hematological response (CHR) and 70.8% and 71.8% achieving molecular response (MR) according to the ELN2009 and 2013 criteria respectively. Patients with increased Immunoglobulin level after treatment seemed to have a higher MR rate according to the ELN2013 criteria, but the statistical difference was not significant. According to the 2013 criteria, patients with a baseline JAK2V617F VAF ≥75% had a significantly lower MR rate, and those who achieved MR had a significantly lower neutrophil-to-lymphocyte ratio (NLR) after 3 months of treatment. Although 98.2% patients experienced laboratory adverse events, only 6 patients stopping due to adverse reactions.DiscussionThe study found that initiating PEG-IFN at 180ug weekly and adjusting only for adverse events was well-tolerated and may offer superior outcomes to traditional dosing strategies. The 12-month hematological and molecular efficacy were promising, suggesting this approach has the potential to improve long-term survival in PV patients, although further research is needed to confirm these findings. |
|---|---|
| ISSN: | 2234-943X |